For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Universal Health Services, Inc. (UHS) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-14): Designation Gem · Cairn score +46 (−100…+100 Quality+Value blend) · Quality 51 · Value 42 · Sentiment -54 (timing only, not weighted) · Composite fair value $213.57 vs $172.45 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Universal Health Services, Inc.
UHS NYSEUniversal Health Services, Inc. is a healthcare services company that owns and operates a broad network of facilities across the United States. The company focuses on two primary segments: Acute Care Hospital Services and Behavioral Health Services. Its acute care operations include general hospitals, surgical hospitals, freestanding emergency departments, and ambulatory surgery and oncology centers, providing medical, surgical, and emergency care to a wide range of patients. The behavioral health segment delivers inpatient and outpatient services for mental health conditions, substance use disorders, and other behavioral health needs, serving children, adolescents, adults, and seniors. Through these segments, Universal Health Services plays a significant role in the medical care facilities industry, supporting both community-based and specialized care. Headquartered in King of Prussia, Pennsylvania, the company is positioned as a major integrated provider in the U.S. healthcare system, offering essential services that span acute medical treatment, complex behavioral healthcare, and related outpatient services.
Earnings Schedule
Checked daily · calendar updated Aug 14| Print date | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| Jul 27, 2026 | $6.01 | $5.98 -0.5% | — | — |
| May 8, 2026 | $0.11 | $0.13 +18.2% | — | — |
| Apr 27, 2026 | $5.46 | $5.62 +2.9% | — | — |
| Feb 25, 2026 | $5.91 | $5.88 -0.5% | — | — |
Green = beat the estimate, red = missed. An earnings print is the fastest way a thesis changes — our designations should be re-read after each one.
Recent SEC Filings
| Filed | Form | Document |
|---|---|---|
| Aug 13, 2026 | 8-K | View |
| Aug 13, 2026 | 424B5 | View |
| Aug 12, 2026 | FWP | View |
| Aug 10, 2026 | 424B5 | View |
| Aug 7, 2026 | POSASR | View |
| Aug 7, 2026 | 10-Q | View |
| Aug 6, 2026 | SCHEDULE 13G/A | View |
| Jul 28, 2026 | 8-K | View |
| Jul 21, 2026 | 8-K | View |
| May 29, 2026 | 4 | View |
| May 22, 2026 | 8-K | View |
| May 21, 2026 | 4 | View |
Filings link to the SEC’s EDGAR system. Annual/quarterly reports (10-K, 10-Q, 20-F) carry the full story; 8-K/6-K current reports are the fastest signal that something material happened.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 23.10
Total Equity: $7.41B
Shares: 64,462,000
Total Debt: $4.75B
Cash: $137.80M
EBITDA: $2.61B
Total Debt: $4.75B
Cash: $137.80M
Revenue: $17.36B
Revenue: $17.36B
Revenue: $17.36B
Total Equity: $7.41B
Tax Rate: 23.4%
Equity: $7.41B
Total Debt: $4.75B
Cash: $137.80M
Current Liabilities: $3.24B
Long-Term Debt: $4.00B
Total Debt: $4.75B
Total Equity: $7.41B
Shares: 64,462,000
Shares: 64,462,000
CapEx: -$1.02B
Shares: 64,462,000
Stock Price: $168.62
Net Income: $1.49B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 13, 2026 12:49am (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $12.6B | $13.4B | $14.3B | $15.8B | $17.4B |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | $11.3B | $12.4B | $13.1B | $14.1B | $15.4B |
| Operating Income | $1.4B | $1.0B | $1.2B | $1.7B | $2.0B |
| Net Income | $991.6M | $675.6M | $717.8M | $1.1B | $1.5B |
| EBITDA | $1.9B | $1.6B | $1.7B | $2.3B | $2.6B |
| EPS | $11.99 | $9.23 | $10.35 | $17.16 | $23.42 |
| EPS (Diluted) | $11.82 | $9.14 | $10.23 | $16.82 | $23.10 |
Balance Sheet (Annual)
Last updated: Aug 3, 2026 12:44pm (10d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $115.3M | $102.8M | $119.4M | $126.0M | $137.8M |
| Total Current Assets | $2.3B | $2.5B | $2.8B | $2.8B | $3.4B |
| Total Assets | $13.1B | $13.5B | $14.0B | $14.5B | $15.5B |
| Current Liabilities | $2.0B | $1.9B | $2.0B | $2.2B | $3.2B |
| Long-Term Debt | $4.1B | $4.7B | $4.8B | $4.5B | $4.0B |
| Total Liabilities | $6.9B | $7.5B | $7.8B | $7.7B | $8.1B |
| Total Equity | $6.2B | $6.0B | $6.2B | $6.8B | $7.4B |
| Retained Earnings | $6.6B | $6.5B | $6.8B | $7.4B | $8.0B |
Cash Flow (Annual)
Last updated: Aug 13, 2026 12:49am (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $883.7M | $996.0M | $1.3B | $2.1B | $1.9B |
| Capital Expenditure | -$855.7M | -$734.0M | -$743.1M | -$943.8M | -$1.0B |
| Free Cash Flow | $28.0M | $262.0M | $524.7M | $1.1B | $849.2M |
| Acquisitions (net) | -$105.4M | -$20.3M | -$3.7M | -$19.0M | -$47.8M |
| Net Debt Issued / (Repaid) | -$3.0B | -$89.4M | -$85.5M | -$2.6B | -$43.5M |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$1.2B | -$832.9M | -$547.4M | -$670.8M | -$968.0M |
| Net Change in Cash | -$1.1B | $21.9M | $13.6M | $10.3M | $46.6M |
Growth Trends (YoY %)
Last updated: Aug 13, 2026 12:49am (1d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +6.0% | +6.6% | +10.8% | +9.7% |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | -26.4% | +17.1% | +43.1% | +18.6% |
| Net Income Growth | -31.9% | +6.2% | +59.1% | +30.4% |
| EBITDA Growth | -16.4% | +10.0% | +30.0% | +15.3% |
Dividend History (Last 20)
Last updated: Aug 13, 2026 12:14am (1d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-06-08 | $0.20 | — | — | — |
| 2026-03-02 | $0.20 | — | — | — |
| 2025-12-01 | $0.20 | — | — | — |
| 2025-09-02 | $0.20 | — | — | — |
| 2025-06-02 | $0.20 | — | — | — |
| 2025-03-03 | $0.20 | — | — | — |
| 2024-12-03 | $0.20 | — | — | — |
| 2024-09-03 | $0.20 | — | — | — |
| 2024-06-03 | $0.20 | — | — | — |
| 2024-02-29 | $0.20 | — | — | — |
| 2023-11-30 | $0.20 | — | — | — |
| 2023-08-31 | $0.20 | — | — | — |
| 2023-05-31 | $0.20 | — | — | — |
| 2023-02-28 | $0.20 | — | — | — |
| 2022-11-30 | $0.20 | — | — | — |
| 2022-08-31 | $0.20 | — | — | — |
| 2022-05-31 | $0.20 | — | — | — |
| 2022-02-28 | $0.20 | — | — | — |
| 2021-11-30 | $0.20 | — | — | — |
| 2021-08-31 | $0.20 | — | — | — |
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-14 01:53| Case | Growth | Margin | Fair value | vs price ($172.45) |
|---|---|---|---|---|
| Bull — recovery | +17% | 9.7% | $389.68 | +126% |
| Base — stabilizes | +11% | 8.4% | $289.64 | +68% |
| Bear — keeps slipping | +6% | 7.2% | $210.95 | +22% |
| Stress — last quarter repeats | +9% | 8.3% | $264.02 | +53% |
Narrative Economics
market-narrative step).
AI Lens 4th lens · how AI reaches this business · 5-yr
2026-08-13Reimbursement is set by government schedules and multi-year payer contracts, not by competitive price discovery, so AI-driven cuts in coding, documentation, prior-auth handling, scheduling and back-office labor across ~400 facilities drop straight into operating margin rather than being competed away.
Payers are deploying AI in utilization review and automated denial at scale; the highest-value target is exactly UHS's behavioral inpatient length-of-stay and acute case-mix intensity, so the provider's own AI gains can be transferred to insurers through denials, downgrades and slower cash conversion.
Whether the AI claims arms race nets in providers' or payers' favor — observable in denial and appeal-overturn rates, days in A/R, bad debt provision, and behavioral segment average length of stay versus admissions growth.
Licensed and certificate-of-need-constrained bed capacity (especially psychiatric, which almost nobody can newly permit), accreditation, in-network payer contracts, and a recruited base of psychiatrists and nurses in supply-short markets.
AI Lens thesis
UHS is a physical-asset, licensed-capacity business whose economics are decided by volume, acuity, reimbursement rates and labor cost — none of which cheap intelligence directly creates or destroys. AI reaches it through three channels: (1) internal cost — revenue cycle, coding, ambient documentation, staffing optimization and centralized shared services, where a 100k+ employee base and 11.5% operating margin mean even 1pp of labor/admin savings is a large earnings delta and, because prices are administratively set, that saving is retained rather than passed through; (2) the payer interface, where insurer AI raises denial density and attacks behavioral LOS and case-mix, potentially confiscating those same gains; (3) demand routing, where AI triage, digital mental-health tools and hospital-at-home monitoring could shave low-acuity outpatient volume while doing nothing to the acute psych and surgical cases that carry margin. Entrant threat is near zero — no amount of cheap software produces a licensed psychiatric hospital.
What the market may be underestimating
Upside Behavioral health is the least digitized, most documentation-heavy, most staffing-constrained care setting in the pool — ambient documentation plus AI scheduling can lift effective clinician capacity in a market where UHS is supply-constrained, converting a labor bottleneck into incremental census at high incremental margin.
Downside AI-assisted audit and coding-pattern analytics (RAC, payer, DOJ) can retrospectively attack case-mix intensity and behavioral admission criteria across a large facility base, turning documentation transparency into recoupment and reputational exposure rather than efficiency.
Outcome range spread 37
Claude Reading
Starting with the raw tape: UHS printed $17.36B in 2025 revenue (+9.7% YoY) with net income of $1.49B, and the TTM run-rate through Q2 2026 is roughly $18.1B revenue and $1.53B NI. That's a 7.4x trailing P/E on a business generating $1.86B operating cash flow, $849M FCF after a heavy $1.02B capex year, ROE of 20%, ROIC of 12.7%. Debt/equity 0.64, EV/EBITDA 5.96. These are not distressed multiples — they're a market saying "we don't believe the margin." And the quarterly trajectory partially validates that skepticism: net margin went 9.9% in Q4 2025 → 7.8% → 7.7% in the most recent two quarters. Q4 was clearly a peak, boosted by what looks like Medicaid supplemental payment recognition (a recurring UHS pattern). Strip Q4 and you're looking at a business running at ~7.8% net margin, not 8.6%. On $18B revenue that's ~$1.4B NI, or roughly $21 EPS on ~66M shares — still a 8x P/E, still cheap, but the "44% earnings CAGR" is a base-effect artifact from 2022's depressed $675M print, not a forward rate.
Where I part ways with the synthesis: the $216 fair value / +31% call is directionally right but overstated. The composite is anchoring on a 2025 earnings number that included the peak-margin Q4 and an FCF conversion (57% of NI) that's structurally mediocre because capex is running at $1B+ as UHS builds out behavioral capacity. If I normalize NI to $1.4B and put a 10x multiple on it — reasonable for a levered hospital operator with real regulatory tail risk — I get $210/share equity value, roughly $212 with the modest net-debt haircut… actually not far from synthesis, but the path there requires believing normalized margins hold. The Market Forces model flagging "margin expansion likely peaking" is corroborated by the Q1/Q2 2026 tape and deserves more weight than the synthesis gave it. The Narrative layer's read that this is fundamentals-driven, not story-driven, is correct and important: there's no re-rating catalyst coming from sentiment shift — it has to come from margin durability quarter after quarter.
The contrarian case a skeptic would press: (1) behavioral health is UHS's crown jewel and it's exactly where DOJ scrutiny, state Medicaid rate resets, and staffing-ratio regulation land hardest — a single adverse settlement or Medicaid rebasing in Texas/California could take 150-200bps off segment margin; (2) $4.75B debt against $138M cash and a 1.05 current ratio is thin liquidity for a business that needs to keep spending on capex; refinancing risk is modest but real if rates stay sticky and hospital cash flows compress; (3) the 7.4x P/E has been the multiple for years — HCA, THC and UHS all trade single-digit for structural reasons (payer mix uncertainty, ACA political risk, for-profit hospital reputational discount) and betting on multiple expansion is betting against a decade of market consensus. (4) The most recent two quarters show revenue growth decelerating from 9.7% YoY to a Q2 pace closer to 8.4%, and earnings growth compressing hard sequentially. This is a company mid-normalization, not mid-acceleration.
I land at partial agreement with the undervalued verdict but dissent on magnitude. Fair value is closer to $200-210 than $226, and the path to realize it requires 3-4 more quarters of 7.5%+ net margin without a regulatory shock. At $168.62 you're paying 8x normalized earnings for a 10% revenue grower with 12.7% ROIC and real (if bounded) tail risks — that's a starter position, not a table-pound. The asymmetry works: downside to $140 (7x on shocked earnings) is ~17%, upside to $210 is ~25%, and you collect a small dividend plus buybacks along the way. I'd size at half-conviction, add on any behavioral-segment regulatory scare that knocks it to $150, and trim into $200+ rather than holding for the $226 synthesis target which assumes the market re-rates a business it has structurally discounted for a decade. The synthesis is too aggressive on the fair value anchor; Market Forces is closer to right on the margin trajectory; the underlying stock is still cheap enough to own.
GPT Reading
What stands out is that UHS is not just “cheap on multiples”; it is in the middle of a real earnings recovery that the stock still seems to discount as temporary. Revenue has gone from $12.64B in 2021 to $17.36B in 2025, a 37% lift, while net income rose from $991.6M to $1.49B despite a 2022-2023 trough. More importantly, the recent run-rate is stronger than the annual snapshot: the last four quarters sum to roughly $18.13B of revenue and about $1.53B of net income, and the first half of 2026 alone produced $707.1M of earnings on $9.14B of revenue. That implies the business is tracking ahead of 2025 on both sales and profit dollars even with quarterly margins settling around 7.7%-7.8% rather than the unusually strong 9.9% of 4Q25. At $10.21B market cap and a 7.5x P/E, the market is paying a distressed-ish multiple for a company putting up nearly 10% recent revenue growth and 30% recent earnings growth. For a hospital operator with demonstrated resilience and an 11.5% operating margin in 2025, that looks too harsh.
The quality of those earnings is also better than the “low multiple for a reason” shorthand suggests. Operating cash flow was $1.86B in 2025 against $1.49B of net income, so earnings are converting to cash rather than being flattered by accruals. Even after very heavy capex of $1.02B, free cash flow was still $849.2M. That matters because this is not an asset-light software business where low capex can hide fragility; UHS is investing more than a billion dollars a year into facilities and still throwing off an 8%-plus FCF yield on market cap. Balance sheet risk is real but not alarming in context: $4.75B of debt against $7.41B of equity, with debt/equity of 0.64, is manageable for a business with nearly $2.0B of operating income and about $1.9B of operating cash flow. The tiny cash balance of $137.8M looks stark in isolation, but for a steady payer/collector in healthcare services, recurring cash generation is more relevant than quarter-end cash.
The deeper point is that the market seems anchored to a narrative of structurally impaired margins, while the actual numbers show a business that has already climbed well off that concern. Net margin improved from 5.0% in 2023 to 7.2% in 2024 to 8.6% in 2025, and the latest two quarters are holding near 7.7%-7.8% despite lapping stronger comps. That is not evidence of collapse; it is evidence that 2025 may have contained a bit of peak benefit, but the new floor is materially above the 2022-2024 level. If UHS merely earns around $1.45B-$1.55B annually over the next year, today’s price implies something like 6.6x-7.0x earnings. For a company generating 20% ROE and 12.7% ROIC, that is too low unless you believe profits are about to roll over meaningfully. I do not see that in the reported trend. My read is straightforward: UHS is undervalued because the stock still prices a margin giveback that has not shown up in the income statement.
The strongest case against that view is that hospital earnings can look optically cheap right before reimbursement and labor pressure bites. The quarterly revenue line has flattened sequentially around $4.49B-$4.64B over the last four quarters, and the “decelerating” revenue confidence tag is not wrong; growth versus prior year remains good, but the acceleration phase may be over. The current ratio of 1.05 is not generous, cash is thin, and this is a capital-intensive model that required over $1.0B of capex just to produce $849M of free cash flow. If margins normalize not at 7.7%-8.0% but back toward 6%-6.5%, earnings power would be much lower than the trailing figures suggest, and then a single-digit P/E would be justified. There is also a fair governance/political discount on for-profit behavioral and acute care operators that does not go away simply because the math screens cheap. A smart bear would say the multiple is low because these are peak earnings in a politically exposed business, not because the market missed an obvious bargain.
What would change my mind is not a headline about valuation but a break in operating stability. If the next two quarters show revenue growth falling below about 4%-5% y/y while net margin drops into the low-6% range, that would tell me 2025-1H26 profitability was indeed cyclical and transient. I would also get more cautious if free cash flow fell materially below $600M annually without a clear high-return growth payoff, or if debt moved higher while earnings flattened. Conversely, if UHS can sustain quarterly net income around $325M-$375M on revenue above $4.6B and keep operating cash flow comfortably ahead of net income, I think the stock deserves at least a 9x-10x earnings multiple, which points to a share price closer to $200-$220 than $169.
Grok Reading
The raw numbers on UHS describe a business that has compounded through a genuine earnings recovery rather than a one-quarter spike. Revenue climbed from $12.64B in 2021 to $17.36B in 2025, a 10.3% CAGR, while net income more than doubled off the 2022–2023 trough to $1.49B. Operating income expanded from $1.00B to $1.99B over the same span, lifting the operating margin to 11.5% and ROE to 20.1%. Free cash flow of $849M against a $10.2B equity value produces an FCF yield near 8.3%, and the stock clears every cheapness screen that matters for a mature hospital operator: 7.5x trailing earnings, 6.0x EV/EBITDA, 0.64x sales, 1.5x book. At $168.62 the market is handing you growth for free relative to any no-growth DCF floor near the mid-$200s that the synthesis models imply. That is the core story the data tell: operationally competent, cash-generative, and priced as if something is broken.
What stands out on closer inspection is that the break may already be visible in the quarterly tape. Net margin peaked at 9.9% in the December 2025 quarter on $4.49B of revenue and $446M of net income; the subsequent two quarters printed 7.8% and 7.7% even as revenue kept rising to $4.50B and $4.64B. That is not noise—it is labor inflation and reimbursement friction reasserting themselves after a favorable stretch. The balance sheet reinforces the caution: $4.75B of total debt against only $138M of cash leaves net leverage elevated and the current ratio at a thin 1.05. Capex of $1.02B consumed more than half of operating cash flow, so the $849M FCF figure is real but not fortress-like. The secondary signal flagging decelerating quarterly revenue trend is consistent with this picture. The market’s 7.5x multiple is therefore not pure irrationality; it is a discount for margin mean-reversion risk and a lightly cash-backed capital structure.
I still come down undervalued. A 20% ROE business growing top-line high-single to low-double digits, throwing off mid-to-high single-digit FCF yields, and trading below 8x earnings does not need heroic assumptions to be worth more than $168. Even if net margins settle permanently in the 7.5–8.0% band rather than the 8.6% 2025 print, the earnings power supports a mid-teens multiple that would re-rate the shares into the $200–230 zone. The behavioral-health segment’s secular demand tailwind and the dual-segment diversification remain intact; nothing in the income statement suggests volume collapse. The valuation synthesis calling for roughly $216–226 is directionally correct, though I would shave a few points off for the leverage and the margin fade already in evidence.
The strongest opposing case cites exactly those Q1–Q2 2026 margin prints, the $4.75B debt stack, and the structural labor/reimbursement headwinds that make 2025’s profitability look peak-cycle. A smart bear would also note that earnings CAGR of 44% is largely recovery math off a depressed base and will normalize hard, that EV/revenue under 1.0x has been a value trap in for-profit hospitals before, and that the narrative layer’s own admission—that most of the DCF discount is fundamentals, not story—means the cheapness is earned. I weigh this seriously but ultimately secondary: the absolute cash generation and the still-expanding revenue base give the equity a floor that pure multiple-compression bears understate. An 8% FCF yield with positive volume trends is not a value trap until FCF itself rolls over.
I would flip if two consecutive quarters print net margins below 7% with revenue growth slipping under 5%, or if free cash flow for the next full year falls under $600M. Conversely, a return to 9%+ net margins with stable labor metrics would make the current price look like a clear miss and push conviction higher.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · four lenses
UHS is executing well as a mature earner: revenue grew from $12.64B (2021) to $17.36B (2025), a ~8% CAGR, while operating margin recovered from a 2022 trough of 7.5% back to 11.5% and net income climbed from $675.6M to $1.49B. Earnings quality is clean — OCF/NI of 1.44x, accruals -2.9% of assets, Altman Z of 3.03 in the safe zone — so the reported earnings appear real. FCF of $849M in the latest year (down from $1.12B prior, worth watching) comfortably funds capex and buybacks. Capital allocation is a clear strength: diluted share count fell from 83.7M to 64.5M, a -6.3% CAGR, with buyback/SBC at ~960% — SBC dilution (0.6% of revenue) is being overwhelmed by repurchases, concentrating per-share value meaningfully. The concern is the balance sheet: net debt of $4.61B against just $137.8M of liquid cash, with $748.2M of short-term debt exceeding cash on hand — refinancing exposure is real, though FCF easily services it. Overall this reads as a solidly run, moderately leveraged healthcare operator with improving profitability and shareholder-friendly capital returns; the leverage prevents a fortress designation but does not threaten the business.
Verify before trusting this (5)
- Debt maturity schedule and refinancing terms for the $748.2M short-term debt
- Payor mix and any concentration risk (Medicare/Medicaid rate exposure)
- Behavioral Health vs. Acute Care segment margin contribution and trends
- Reason FCF fell ~24% YoY despite record net income (working capital, capex, litigation payments)
- Insider transaction pattern (not provided in evidence) to confirm alignment
Price is $172.45 against a composite FV of $216 and a signal-adjusted FV of $226, implying ~25-31% upside. The EPV floor at $189 is the most conservative anchor and still sits ~10% above spot, which is meaningful because EPV assumes no growth - it says the current earnings power alone is worth more than the market cap. DCF at $230 is directionally supportive but I weight it less given hospital operators carry real leverage and labor-cost risk that a growth-y DCF can under-penalize. Earnings quality is high (score 3), so no haircut needed to the deserved value. What is priced in: the market is applying the standard for-profit-hospital discount - ESG stigma on behavioral health, Medicare rate anxiety, and $4.6B net debt with thin cash. What is not priced in: mid-single-digit revenue growth, margins recovering to double digits, and an aggressive buyback that is compounding per-share value. Combining a strong (but leveraged) business with an EPV floor above price gives a genuine, if modest, gap. Not a table-pounder - the discount exists for identifiable reasons - but the math supports Modestly Cheap rather than fair.
Verify before trusting this (4)
- Medicare rate updates and behavioral health reimbursement trends in next 10-Q
- Labor cost per adjusted admission trajectory - is margin recovery holding
- Buyback pace and any debt paydown vs new borrowings
- Any regulatory/legal developments in behavioral health facilities
The macro backdrop is mildly constructive (VIX 14.6, S&P near highs, risk-on regime) and UHS's beta of 1.06 means the tape isn't punishing or lifting it much either way. But sentiment on this specific name is negative: the stock is down roughly 20% over six months, the active narrative around for-profit hospital operators is low-intensity and defensive rather than exciting, and behavioral-health regulatory/reputational overhang keeps the multiple compressed. There is no cult, no story to defend the name in a rotation. On top of that, a Sunday-published 'reasons to sell UHS' article is exactly the kind of retail-sentiment reinforcement that keeps a wounded name wounded. Higher-for-longer rates (10y 4.7%) and a stretched market PE 26 add a mild valuation-compression headwind sector-wide, but the bigger issue is name-specific: momentum is broken, the tape isn't hostile enough to matter, and there is no positive narrative catalyst pulling capital in. Net pressure is a moderate headwind — not a collapse, just steady drift as the story fails to attract marginal buyers.
Verify before trusting this (4)
- Whether analyst target revisions turn lower after next print
- Any behavioral-health regulatory headlines that would harden the bear thesis
- Signs of sector rotation into defensive healthcare that could catch UHS as a laggard bid
- Whether the stock stabilizes around $170 or breaks lower on volume
UHS is a physical-asset, licensed-capacity business whose economics are decided by volume, acuity, reimbursement rates and labor cost — none of which cheap intelligence directly creates or destroys. AI reaches it through three channels: (1) internal cost — revenue cycle, coding, ambient documentation, staffing optimization and centralized shared services, where a 100k+ employee base and 11.5% operating margin mean even 1pp of labor/admin savings is a large earnings delta and, because prices are administratively set, that saving is retained rather than passed through; (2) the payer interface, where insurer AI raises denial density and attacks behavioral LOS and case-mix, potentially confiscating those same gains; (3) demand routing, where AI triage, digital mental-health tools and hospital-at-home monitoring could shave low-acuity outpatient volume while doing nothing to the acute psych and surgical cases that carry margin. Entrant threat is near zero — no amount of cheap software produces a licensed psychiatric hospital.
None surfaced.
Verify before trusting this (8)
- SG&A and admin cost per admission
- Salaries/wages as % of revenue
- CMS market-basket productivity cuts
- Contract labor as % of salaries
- Nurse/psychiatrist vacancy rates
- New behavioral bed additions
- Behavioral average length of stay
- Revenue per adjusted patient day